NIDA Program Project Grant Applications (P01 Clinical Trial Optional)
ID: 345314Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/345314

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-064.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the NIDA Program Project Grant (P01 Clinical Trial Optional), aimed at supporting collaborative, multidisciplinary research addressing critical issues related to substance use and its consequences. This funding opportunity requires applicants to propose a minimum of three interrelated research projects that demonstrate scientific merit and thematic cohesion, supported by an administrative core, to foster synergistic outcomes that enhance the overall program's impact. This initiative reflects NIH's commitment to advancing addiction research through collaboration across various fields, including neuroscience, genetics, and health services. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by January 7, 2026, and can find additional information and application guidelines at NIH Grants. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-064-Full-Announcement.html
    PAR-23-064.html
    The National Institute on Drug Abuse (NIDA) is inviting grant applications for Program Project Grants (P01) with an optional clinical trial component, focusing on multidisciplinary research addressing critical issues related to substance use and its consequences. This opportunity aims to gather collaborative teams to explore areas such as neuroscience, genetics, HIV/AIDS, and health services that affect individuals with substance use disorders. Applications must include at least three interrelated research projects demonstrating scientific merit and similar thematic goals, supported by an administrative core. The application timeline indicates several submission deadlines in 2023 and 2024, with a maximum project duration of up to five years and no budget limits specified. A critical component of the application is the Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity and address disparities in the research context. Eligible applicants include various entities, such as higher education institutions and nonprofit organizations. The document outlines comprehensive instructions on applications, evaluations, eligibility, and submission processes, emphasizing adherence to NIH guidelines throughout. This funding opportunity reflects NIH's commitment to advancing addiction research by fostering collaboration and innovation across multiple disciplines.
    Similar Opportunities
    NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIDA Animal Genomics Program (U01), aimed at exploring the genetic and molecular factors associated with substance use disorders (SUD). This cooperative agreement encourages research that identifies genetic, genomic, and epigenetic variants influencing addictive behaviors and related comorbidities, utilizing diverse methodologies such as multi-omics and artificial intelligence. The program is open to a wide range of eligible applicants, including higher education institutions and nonprofit organizations, with no budget cap for proposals, although budgets should reflect actual project needs. Applications are due by February 12, 2027, with an opening date for submissions on January 11, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) to support institutional research career development programs aimed at clinician scientists. This grant is designed to provide intensive supervised research training and career development experiences, ultimately leading to research independence in the field of substance use and substance use disorders. The program encourages applications focusing on various scientific areas, including neuroimaging, genetics, medication development, and implementation science, among others. Interested applicants from private institutions of higher education should prepare for the upcoming Notice of Funding Opportunity (NOFO), with an estimated synopsis post date of July 3, 2025, and a close date of August 5, 2025. For further inquiries, applicants can contact Lindsey Friend, Ph.D., at NIDA via email at NIDATraining@nida.nih.gov or by phone at 301-402-1428.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Research Education Program for Clinical Researchers and Clinicians under Funding Opportunity Number PAR-25-204, aimed at enhancing the training of clinicians and clinical researchers in substance use disorder (SUD) research. This program seeks to address the shortage of qualified professionals in the field by supporting educational activities that develop skills and provide hands-on research experiences, particularly targeting underrepresented groups in the workforce. With a budget of up to $350,000 annually for a project duration not exceeding five years, the program is open for applications starting February 11, 2025. Interested applicants can find more information and guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders" (R61/R33), aimed at supporting innovative clinical research that explores the neurobiological mechanisms underlying substance use disorders (SUD). This initiative encourages applications that investigate neural circuitry and cognitive processes affecting substance use behavior, particularly in the context of the ongoing public health crisis related to SUDs, including the opioid epidemic. The R61/R33 mechanism allows for up to five years of funding, divided into an initial two-year R61 phase and a potential three-year R33 phase, contingent upon meeting specified milestones. Interested applicants can find more information and submit proposals by the application due date of March 13, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)" aimed at supporting research into effective interventions for substance use disorders (SUDs) and overdose. This cooperative agreement encourages applications for preclinical and clinical studies focusing on pharmacotherapies, device-based treatments, digital therapeutics, and behavioral interventions, with the goal of advancing these interventions towards regulatory approval or clinical adoption. The funding amount can reach up to $3 million, and applications are due by 5:00 PM local time, with multiple submission cycles from October 2025 to August 2028. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
    National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), invites applications for Program Project grants (P01) aimed at fostering collaborative, multidisciplinary cancer research for the years 2023, 2024, and 2025. Applicants must propose at least three interrelated research projects and an Administrative Core, all centered around a common theme within the expansive field of cancer research, which includes areas such as cancer biology, prevention, diagnosis, treatment, and control. This funding opportunity is crucial for advancing cancer research and enhancing the effectiveness of collaborative efforts, with applications due by May 7, 2026. Interested parties can find more information and application guidelines at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Accelerating the Pace of Substance Use Research Using Existing Data." This initiative invites applications that propose innovative analyses of existing social science, behavioral, administrative, and neuroimaging data to investigate the etiology and epidemiology of substance use behaviors and related disorders, including HIV prevention and health service utilization. The program aims to leverage public datasets to enhance understanding of substance use trajectories and effective prevention strategies, particularly focusing on underrepresented populations and health disparities. A total funding commitment of $2 million is available for fiscal year 2026, with applications due by January 25, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)," aimed at advancing translational research in the field of substance use. This initiative encourages researchers to engage in a two-phase research process, starting with an R61 planning phase lasting up to two years, followed by an R33 phase for larger studies that may extend up to four years, contingent upon meeting specific milestones. The program emphasizes the importance of community stakeholder engagement and mandates a Plan for Enhancing Diverse Perspectives (PEDP) in all proposals to ensure inclusivity in research development. Interested applicants can find more information and submit their proposals by December 14, 2026, and should direct inquiries to grantsinfo@nih.gov.